Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

NCT02934256 is registered in ClinicalTrials.gov with Li Peng as lead sponsor.

NCT NCT02934256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02934256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Lead sponsor
Li Peng
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
July 31, 2018
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 2, vestibular schwannoma